Polymorphisms of innate pattern recognition receptors,response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients

Abstract

Background: Interferon-beta therapy of patients with relapsing—remitting multiple sclerosis involves repeated ‘immunizations’ with exogenous protein solutions. Innate pattern recognition receptors play an important role in immune responses towards foreign substances and may thus be related to treatment outcome.

Objective: To determine the genotypes at 42 single nucleotide polymorphism loci in selected pattern recognition receptors for 567 prospectively followed relapsing—remitting multiple sclerosis patients treated with recombinant interferon-beta, and test for relationships to several outcome parameters, including formation of interferon-beta neutralizing antibodies.

Results: The results suggest an association between the rs5743810 polymorphism (Ser249Pro) of TLR6 and development of neutralizing antibodies after 24 months of therapy in males (p = 0.00002), but not in females (p = 0.2). This association survived crude Bonferroni correction (p _corrected = 0.02). Additional associations were observed in carriers of the TLR2-rs5743708 and NOD2-rs3135499 SNPs (time to relapse), the TLR7-rs179008 and NOD1-rs2075820 SNPs (time to disease progression) and the TLR4-rs7873784, TLR9-rs5743836, and NOD2-rs2066842 SNPs (frequency of neutralizing antibodies development). All of these, however, failed to survive correction for multiple testing. There were no significant differences between interferon-beta responders and non-responders for any of the investigated single nucleotide polymorphisms.

Conclusions: The rs5743810 polymorphism of TLR6 may be involved in development of anti-interferon-beta antibodies in males, although further studies are required to firmly establish this.

Keywords

multiple sclerosis pattern recognition receptors toll-like receptors interferon-beta neutralizing antibodies single nucleotide polymorphism gender

Get full access to this article

View all access options for this article.

References

Compston A. and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.

Rudick RA , Goodkin DE , Jacobs LD , et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Neurology 1997; 49: 358-363.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.

Goodin DS , Frohman EM , Hurwitz B. , et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology . Neurology 2007; 68: 977-984.

Malucchi S. , Gilli F. , Caldano M. , et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008; 70: 1119-1127.

Ross C. , Clemmesen KM , Svenson M. , et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration . Ann Neurol 2000; 48: 706-712.

Sorensen PS , Ross C. , Clemmesen KM , et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.

Sorensen PS , Tscherning T. , Mathiesen HK , et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67: 1681-1683.

10.

Rio J. , Nos C. , Tintore M. , et al. Assessment of different treatment failure criteria in a cohort of relapsingremitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002; 52: 400-406.

11.

Rio J. , Nos C. , Tintore M. , et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006 ; 59: 344-352.

12.

Rudick RA , Lee JC , Simon J. , Ransohoff RM and Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.

13.

Sturzebecher S. , Wandinger KP , Rosenwald A. , et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126: 1419-1429.

14.

Villoslada P. , Oksenberg JR , Rio J. and Montalban X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2004; 62: 1653.

15.

Waubant E. , Vukusic S. , Gignoux L. , et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-189.

16.

Vinuesa CG , Tangye SG , Moser B. and Mackay CR Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5: 853-865.

17.

Hoffmann S. , Cepok S. , Grummel V. , et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008; 83: 219-227.

18.

Stickler M. , Valdes AM , Gebel W. , et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta . Genes Immun 2004; 5: 1-7.

19.

Hemmer B. , Stuve O. , Kieseier B. , Schellekens H. and Hartung HP Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005; 4: 403-412.

20.

Creagh EM and O’Neill LA TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27: 352-357.

21.

Biragyn A. , Ruffini PA , Leifer CA , et al. Toll-like receptor 4-dependent activation of dendritic cells by betadefensin 2. Science 2002; 298: 1025-1029.

22.

Jiang D. , Liang J. , Fan J. , et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-1179.

23.

Park JS , Gamboni-Robertson F. , He Q. , et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917-C924.

24.

Akira S. , Takeda K. and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity . Nat Immunol 2001; 2: 675-680.

25.

Koch-Henriksen N. and Sorensen PS The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler 2000; 6: 172-175.

26.

Enevold C. , Oturai AB , Sorensen PS , Ryder LP , Koch-Henriksen N and Bendtzen K. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. J Neuroimmunol 2009; 212(1-2): 125-131.

27.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.

28.

Bendtzen K. Anti-IFN BAb and NAb antibodies: a mini-review . Neurology 2003; 61(9; Suppl 5): S6-10.

29.

Sherry ST , Ward MH , Kholodov M. , et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-311.

30.

The IIPGA database. http://www.innateimmunity.net/ . Accessed February 2006.

31.

The SNPper database. http://snpper.chip.org/bio/ . Accessed February 2006.

32.

Liu K. and Muse SV PowerMarker: an integrated analysis environment for genetic marker analysis . Bioinformatics 2005; 21: 2128-2129.

33.

Guo SW and Thompson EA Performing the exact test of Hardy-Weinberg proportion for multiple alleles . Biometrics 1992; 48: 361-372.

34.

Roxburgh RH , Seaman SR , Masterman T. , et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.

35.

Alonso A. , Jick SS , Olek MJ and Hernan MA Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol 2007; 254: 1736-1741.

36.

Compston A. The genetic epidemiology of multiple sclerosis . Philos Trans R Soc Lond B Biol Sci 1999; 354: 1623-1634.

37.

Duquette P. , Pleines J. , Girard M. , Charest L. , Senecal-Quevillon M. and Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992; 19: 466-471.

38.

Nguyen LT , Ramanathan M. , Weinstock-Guttman B. , Baier M. , Brownscheidle C. and Jacobs LD Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003; 209: 93-99.

39.

Orton SM , Herrera BM , Yee IM , et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study . Lancet Neurol 2006; 5: 932-936.

40.

Byun E. , Caillier SJ , Montalban X. , et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344.

41.

Comabella M. , Craig DW , Morcillo-Suarez C. , et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-978.

42.

De Jager PL , Jia X. , Wang J. , et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.

43.

O’Doherty C. , Villoslada P. and Vandenbroeck K. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev 2007; 18: 211-222.

44.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.

45.

PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.

46.

Deisenhammer F. and Giovannoni G. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis . Mult Scler 2004; 10: 713-714.

47.

Francis GS , Rice GP and Alsop JC Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.

48.

Kappos L. , Clanet M. , Sandberg-Wollheim M. , et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.

49.

Petkau AJ , White RA , Ebers GC , et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126-138.

50.

Deisenhammer F. , Reindl M. , Harvey J. , Gasse T. , Dilitz E. and Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239-1243.

51.

Goris A. , Epplen C. , Fiten P. , et al. Analysis of an IFNgamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease . J Interferon Cytokine Res 1999; 19: 1037-1046.

52.

Goris A. , Heggarty S. , Marrosu MG , Graham C. , Billiau A. and Vandenbroeck K. Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis: delineation of a 118-kb interval around interferon-gamma (IFNG) that is involved in male versus female differential susceptibility. Genes Immun 2002; 3: 470-476.

53.

Kantarci OH , Goris A. , Hebrink DD , et al. IFNG polymorphisms are associated with gender differences in susceptibility to multiple sclerosis. Genes Immun 2005; 6: 153-161.

54.

Vandenbroeck K. , Opdenakker G. , Goris A. , Murru R. , Billiau A. and Marrosu MG Interferon-gamma gene polymorphism-associated risk for multiple sclerosis in Sardinia. Ann Neurol 1998; 44: 841-842.

55.

Kantarci OH , Hebrink DD , Schaefer-Klein J. , et al. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression . Arch Neurol 2008; 65: 349-357.

56.

Petereit HF , Nolden S. , Schoppe S. , Bamborschke S. , Pukrop R. and Heiss WD Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002; 8: 492-494.

57.

Dhiman N. , Ovsyannikova IG , Vierkant RA , et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008; 26: 1731-1736.

58.

Trojano M. , Pellegrini F. , Paolicelli D. , et al. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci 2009; 286: 109-113.

59.

Hayashi EA , Akira S. and Nobrega A. Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J Immunol 2005; 174: 6639-6647.

60.

Ruprecht CR and Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36: 810-816.

61.

Kormann MS , Depner M. , Hartl D. , et al. Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 2008; 122: 86-92.

62.

Ma X. , Liu Y. , Gowen BB , Graviss EA , Clark AG and Musser JM Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2007; 2: e1318.

63.

Pierik M. , Joossens S. , Van SK , et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006; 12: 1-8.

64.

Stevens VL , Hsing AW , Talbot JT , et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer 2008 ; 123: 2644-2650.

65.

Sun J. , Wiklund F. , Zheng SL , et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97: 525-532.

66.

Tantisira K. , Klimecki WT , Lazarus R. , et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004; 5: 343-346.

67.

Hornung V. , Rothenfusser S. , Britsch S. , et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-4537.

68.

Borsutzky S. , Kretschmer K. , Becker PD , et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 2005; 174: 6308-6313.

69.

Ozinsky A. , Underhill DM , Fontenot JD , et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97: 13766-13771.